Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Purpose To determine the maximally tolerated dose of sorafenib delivered before, during, and after stereotactic body radiation therapy (SBRT) in hepatocellular carinoma (HCC). Methods and Materials Eligible patients had locally advanced Child-Pugh class A HCC, showed Eastern Cooperative Oncology Gro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of radiation oncology, biology, physics biology, physics, 2016-03, Vol.94 (3), p.580-587
Hauptverfasser:	Brade, Anthony M., MD, CM, PhD, Ng, Sylvia, MD, PhD, Brierley, James, MD, Kim, John, MD, Dinniwell, Robert, MD, MSc, Ringash, Jolie, MD, Wong, Rebecca R., MD, Cho, Charles, MD, Knox, Jennifer, MD, Dawson, Laura A., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - surgery Carinoma CLINICAL TRIALS Dose Fractionation Female GY RANGE 10-100 Hematology, Oncology and Palliative Medicine Humans Intestines - drug effects Intestines - radiation effects LIVER Liver - drug effects Liver - radiation effects Liver Neoplasms - drug therapy Liver Neoplasms - surgery Male Maximum Tolerated Dose Middle Aged NEOPLASMS Niacinamide - administration & dosage Niacinamide - adverse effects Niacinamide - analogs & derivatives PATIENTS Phenylurea Compounds - administration & dosage Phenylurea Compounds - adverse effects RADIATION DOSES Radiology RADIOLOGY AND NUCLEAR MEDICINE Radiosurgery - adverse effects Radiosurgery - methods RADIOTHERAPY Radiotherapy Dosage TOXICITY
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose To determine the maximally tolerated dose of sorafenib delivered before, during, and after stereotactic body radiation therapy (SBRT) in hepatocellular carinoma (HCC). Methods and Materials Eligible patients had locally advanced Child-Pugh class A HCC, showed Eastern Cooperative Oncology Group performance status 0-1, and were ineligible for standard local-regional therapies. Sorafenib was dose escalated in 2 strata: ( 1 ) low effective irradiated liver volume (veff)
ISSN:	0360-3016 1879-355X
DOI:	10.1016/j.ijrobp.2015.11.048